Complex Formation between VEGFR2 and the β
BRET
CRISPR/Cas9
NanoBRET
VEGFR2
infantile haemangioma
receptor oligomerisation
β(2)-adrenoceptors
β-arrestin
Journal
Cell chemical biology
ISSN: 2451-9448
Titre abrégé: Cell Chem Biol
Pays: United States
ID NLM: 101676030
Informations de publication
Date de publication:
20 06 2019
20 06 2019
Historique:
received:
21
09
2018
revised:
30
12
2018
accepted:
24
02
2019
pubmed:
9
4
2019
medline:
22
4
2020
entrez:
9
4
2019
Statut:
ppublish
Résumé
Vascular endothelial growth factor (VEGF) is an important mediator of endothelial cell proliferation and angiogenesis via its receptor VEGFR2. A common tumor associated with elevated VEGFR2 signaling is infantile hemangioma that is caused by a rapid proliferation of vascular endothelial cells. The current first-line treatment for infantile hemangioma is the β-adrenoceptor antagonist, propranolol, although its mechanism of action is not understood. Here we have used bioluminescence resonance energy transfer and VEGFR2 genetically tagged with NanoLuc luciferase to demonstrate that oligomeric complexes involving VEGFR2 and the β
Identifiants
pubmed: 30956148
pii: S2451-9456(19)30069-8
doi: 10.1016/j.chembiol.2019.02.014
pmc: PMC6593180
pii:
doi:
Substances chimiques
Fluorescent Dyes
0
Ligands
0
Receptors, Adrenergic, beta-2
0
Luciferases
EC 1.13.12.-
KDR protein, human
EC 2.7.10.1
Vascular Endothelial Growth Factor Receptor-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
830-841.e9Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/L019418/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N020081/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/L013827/1
Pays : United Kingdom
Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Curr Opin Cell Biol. 1999 Apr;11(2):177-83
pubmed: 10209148
Nature. 1999 Dec 23-30;402(6764):884-8
pubmed: 10622253
J Biol Chem. 2000 Jul 28;275(30):23120-6
pubmed: 10770944
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2449-54
pubmed: 11226259
J Biol Chem. 2002 Jan 18;277(3):2028-32
pubmed: 11711543
Circ Res. 2002 Mar 22;90(5):531-8
pubmed: 11909816
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
J Biol Chem. 2002 Nov 22;277(47):44925-31
pubmed: 12244098
Br J Pharmacol. 2003 May;139(2):232-42
pubmed: 12770928
Biol Chem. 2005 Sep;386(9):845-55
pubmed: 16164409
N Engl J Med. 2008 Jun 12;358(24):2649-51
pubmed: 18550886
J Biomol Screen. 2008 Oct;13(9):888-98
pubmed: 18812574
Nat Methods. 2009 May;6(5):343-5
pubmed: 19363495
FASEB J. 2010 Jan;24(1):32-8
pubmed: 19726758
Eur Cytokine Netw. 2009 Dec;20(4):158-63
pubmed: 20167554
Mol Cell Endocrinol. 2011 Jan 15;331(2):222-31
pubmed: 20398727
Endocrinology. 2010 Jul;151(7):2994-3005
pubmed: 20501673
Int J Cancer. 2011 May 15;128(10):2306-16
pubmed: 20715173
Cancer Res. 2010 Sep 15;70(18):7042-52
pubmed: 20823155
Nature. 2011 Jan 13;469(7329):175-80
pubmed: 21228869
Trends Pharmacol Sci. 2011 Aug;32(8):443-50
pubmed: 21612832
Trends Pharmacol Sci. 2011 Sep;32(9):521-33
pubmed: 21680031
Mol Ther. 2011 Sep;19(9):1695-703
pubmed: 21694703
FASEB J. 2011 Oct;25(10):3465-76
pubmed: 21715680
PLoS One. 2011;6(6):e21599
pubmed: 21738726
Curr Opin Struct Biol. 2011 Aug;21(4):567-72
pubmed: 21782416
Blood. 2012 Feb 16;119(7):1781-8
pubmed: 22207738
Genes Cancer. 2011 Dec;2(12):1097-105
pubmed: 22866201
J Med Chem. 2012 Dec 27;55(24):10797-822
pubmed: 23098265
Exp Ther Med. 2012 Oct;4(4):594-604
pubmed: 23170111
J Intern Med. 2013 Feb;273(2):114-27
pubmed: 23216836
Nature. 2013 Mar 28;495(7442):534-8
pubmed: 23515162
Nat Biotechnol. 2013 Sep;31(9):827-32
pubmed: 23873081
FEBS J. 2013 Nov;280(21):5258-68
pubmed: 23992425
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
Pharmacol Rev. 2014 Feb 10;66(2):413-34
pubmed: 24515647
Front Endocrinol (Lausanne). 2014 Mar 05;5:26
pubmed: 24634666
Eur J Histochem. 2014 Mar 17;58(1):2263
pubmed: 24704994
Br J Pharmacol. 2014 Aug;171(16):3827-44
pubmed: 24750014
Cell Rep. 2014 Nov 20;9(4):1306-17
pubmed: 25453753
Curr Opin Struct Biol. 2014 Dec;29:95-101
pubmed: 25460273
Br J Pharmacol. 2015 Jun;172(12):3141-50
pubmed: 25684635
FASEB J. 2015 Jul;29(7):2859-71
pubmed: 25837585
Nat Methods. 2015 Jul;12(7):661-663
pubmed: 26030448
Nat Commun. 2015 Jun 10;6:7380
pubmed: 26060020
Mol Pharmacol. 2015 Sep;88(3):561-71
pubmed: 26138074
Pediatr Int. 2016 Nov;58(11):1130-1135
pubmed: 26991797
Elife. 2016 Apr 07;5:e13876
pubmed: 27052508
Brain Behav Immun. 2016 Oct;57:106-115
pubmed: 27321906
Cell. 2016 Aug 11;166(4):907-919
pubmed: 27499021
Oncogene. 2017 Mar;36(11):1525-1536
pubmed: 27641328
Biochim Biophys Acta Biomembr. 2017 Sep;1859(9 Pt A):1445-1455
pubmed: 27993566
Structure. 2017 Feb 7;25(2):341-352
pubmed: 28111021
J Bone Miner Res. 2017 Jul;32(7):1442-1454
pubmed: 28300321
Biochem Pharmacol. 2017 Jul 15;136:62-75
pubmed: 28392095
Integr Biol (Camb). 2017 May 22;9(5):464-484
pubmed: 28436498
Oncotarget. 2017 Jul 4;8(27):44732-44748
pubmed: 28512254
Sci Rep. 2017 Jun 9;7(1):3187
pubmed: 28600500
Nature. 2017 Oct 26;550(7677):543-547
pubmed: 29045395
Trends Pharmacol Sci. 2018 Feb;39(2):136-147
pubmed: 29132917
Trends Pharmacol Sci. 2018 Feb;39(2):109-122
pubmed: 29157577
Trends Pharmacol Sci. 2018 Feb;39(2):158-174
pubmed: 29277246
Trends Pharmacol Sci. 2018 Feb;39(2):200-208
pubmed: 29478570
Int J Mol Sci. 2018 Apr 23;19(4):null
pubmed: 29690653
Cell Chem Biol. 2018 Oct 18;25(10):1208-1218.e5
pubmed: 30057299
EMBO J. 1997 Dec 1;16(23):7032-44
pubmed: 9384582